Immunitas Therapeutics Launches with $39 Million to Advance Lead Programs to Human Efficacy Studies Based on a Unique Immunology-Focused Drug Development Platform

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/37r4oA3
via IFTTT